Completion rate and impact on physician-patient relationship of video consultations in medical oncology: a randomised controlled open-label trial.

digital health physician-patient relationship shared decision-making smartphone telemedicine

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
11 2020
Historique:
received: 14 07 2020
revised: 13 09 2020
accepted: 15 10 2020
entrez: 18 11 2020
pubmed: 19 11 2020
medline: 19 8 2021
Statut: ppublish

Résumé

Mobile phone video call applications generally did not undergo testing in randomised controlled clinical trials prior to their implementation in patient care regarding the rate of successful patient visits and impact on the physician-patient relationship. The National Center for Tumour Diseases (NCT) MOBILE trial was a monocentric open-label randomised controlled clinical trial of patients with solid tumours undergoing systemic cancer therapy with need of a follow-up visit with their consulting physician at outpatient clinics. 66 patients were 1:1 randomised to receive either a standard in-person follow-up visit at outpatient clinics or a video call via a mobile phone application. The primary outcome was feasibility defined as the proportion of patients successfully completing the first follow-up visit. Secondary outcomes included success rate of further video calls, time spent by patient and physician, patient satisfaction and quality of physician-patient relationship. Success rate of the first follow-up visit in the intention-to-treat cohort was 87.9% (29 of 33) for in-person visits and 78.8% (26 of 33) for video calls (relative risk: RR 0.90, 95% CI 0.70 to 1.13, p=0.51). The most common reasons for failure were software incompatibility in the video call and no-show in the in-person visit arm. The success rate for further video visits was 91.7% (11 of 12). Standardised patient questionnaires showed significantly decreased total time spent and less direct costs for patients (Δmean -170.8 min, 95% CI -246 min to -95.5 min), p<0.0001; Δmean -€14.37, 95% CI -€23.9 to -€4.8, p<0.005) and comparable time spent for physicians in the video call arm (Δmean 0.5 min, 95% CI -5.4 min to 6.4 min, p=0.86). Physician-patient relationship quality mean scores assessed by a validated standardised questionnaire were higher in the video call arm (1.13-fold, p=0.02). Follow-up visits with the tested mobile phone video call application were feasible but software compatibility should be critically evaluated. DRKS00015788.

Sections du résumé

BACKGROUND
Mobile phone video call applications generally did not undergo testing in randomised controlled clinical trials prior to their implementation in patient care regarding the rate of successful patient visits and impact on the physician-patient relationship.
METHODS
The National Center for Tumour Diseases (NCT) MOBILE trial was a monocentric open-label randomised controlled clinical trial of patients with solid tumours undergoing systemic cancer therapy with need of a follow-up visit with their consulting physician at outpatient clinics. 66 patients were 1:1 randomised to receive either a standard in-person follow-up visit at outpatient clinics or a video call via a mobile phone application. The primary outcome was feasibility defined as the proportion of patients successfully completing the first follow-up visit. Secondary outcomes included success rate of further video calls, time spent by patient and physician, patient satisfaction and quality of physician-patient relationship.
FINDINGS
Success rate of the first follow-up visit in the intention-to-treat cohort was 87.9% (29 of 33) for in-person visits and 78.8% (26 of 33) for video calls (relative risk: RR 0.90, 95% CI 0.70 to 1.13, p=0.51). The most common reasons for failure were software incompatibility in the video call and no-show in the in-person visit arm. The success rate for further video visits was 91.7% (11 of 12). Standardised patient questionnaires showed significantly decreased total time spent and less direct costs for patients (Δmean -170.8 min, 95% CI -246 min to -95.5 min), p<0.0001; Δmean -€14.37, 95% CI -€23.9 to -€4.8, p<0.005) and comparable time spent for physicians in the video call arm (Δmean 0.5 min, 95% CI -5.4 min to 6.4 min, p=0.86). Physician-patient relationship quality mean scores assessed by a validated standardised questionnaire were higher in the video call arm (1.13-fold, p=0.02).
INTERPRETATION
Follow-up visits with the tested mobile phone video call application were feasible but software compatibility should be critically evaluated.
TRIAL REGISTRATION NUMBER
DRKS00015788.

Identifiants

pubmed: 33203685
pii: S2059-7029(20)32737-X
doi: 10.1136/esmoopen-2020-000912
pmc: PMC7674103
pii:
doi:

Banques de données

DRKS
['DRKS00015788']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e000912

Informations de copyright

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

Déclaration de conflit d'intérêts

Competing interests: LM is an employee of Minxli, München, Germany.

Auteurs

Thomas Walle (T)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; Clinical Cooperation Unit Virotherapy, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany. Electronic address: t.walle@dkfz-heidelberg.de.

Erkin Erdal (E)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; Department of Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Leon Mühlsteffen (L)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; Minxli AG, Muenchen, Germany.

Hans Martin Singh (HM)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; Clinical Cooperation Unit Virotherapy, German Cancer Research Center, Heidelberg, Germany.

Editha Gnutzmann (E)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Barbara Grün (B)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Helene Hofmann (H)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Alexandra Ivanova (A)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Bruno Christian Köhler (BC)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Felix Korell (F)

Department of Hematology, University Hospital Heidelberg, Heidelberg, Germany.

Athanasios Mavratzas (A)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Andreas Mock (A)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.

Constantin Pixberg (C)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

David Schult (D)

Department of Hematology, University Hospital Heidelberg, Heidelberg, Germany.

Helen Starke (H)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Niels Steinebrunner (N)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Lena Woydack (L)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Andreas Schneeweiss (A)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Mareike Dietrich (M)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Dirk Jäger (D)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.

Johannes Krisam (J)

Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany.

Jakob N Kather (JN)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.

Eva C Winkler (EC)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH